Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Skin Diseases, Viral

ClinicalTrials.gov lists 455 trials for Skin Diseases, Viral or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 30.

MeSH D017193 Infections C01 C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 51 Phase 1/2 Phase 1/2 19 Phase 2 Phase 2 88 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 100 Phase 4 Phase 4 29 Not applicable Not applicable 82 Observational Observational 74 Phase 1 Phase 1 51 Phase 1/2 Phase 1/2 19 Phase 2 Phase 2 88 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 100 Phase 4 Phase 4 29 Not applicable Not applicable 82 Observational Observational 74

Trials per phase

10 of the 455 trials are tagged with Skin Diseases, Viral itself; the rest are tagged with a narrower condition beneath it.

Get the Skin Diseases, Viral report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Skin Diseases, Viral trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 31

1992: 4 trials (Phase 3 2, Phase 2 1, Phase 1 1) 1994: 1 trials (Observational 1) 1995: 2 trials (Phase 1/2 2) 1996: 2 trials (Phase 3 2) 1997: 5 trials (Observational 1, Phase 3 4) 1999: 3 trials (Phase 3 2, Phase 2 1) 2000: 2 trials (Phase 3 1, Phase 2 1) 2001: 3 trials (Phase 3 2, Phase 2 1) 2002: 5 trials (Observational 1, Phase 4 1, Phase 3 3) 2003: 9 trials (Phase 4 2, Phase 3 6, Phase 1 1) 2004: 10 trials (Not applicable 2, Phase 4 1, Phase 3 2, Phase 2 5) 2005: 12 trials (Observational 2, Not applicable 1, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 3) 2006: 14 trials (Observational 3, Phase 4 2, Phase 3 4, Phase 2 1, Phase 1/2 1, Phase 1 3) 2007: 19 trials (Not applicable 3, Phase 4 1, Phase 3 4, Phase 2 7, Phase 1/2 1, Phase 1 3) 2008: 13 trials (Observational 3, Not applicable 2, Phase 4 1, Phase 3 4, Phase 2 2, Phase 1 1) 2009: 19 trials (Observational 7, Not applicable 6, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1 1) 2010: 14 trials (Observational 2, Not applicable 2, Phase 4 3, Phase 3 4, Phase 2/3 2, Phase 1/2 1) 2011: 17 trials (Observational 6, Not applicable 1, Phase 4 2, Phase 3 3, Phase 1/2 2, Phase 1 3) 2012: 23 trials (Observational 6, Not applicable 3, Phase 4 1, Phase 3 6, Phase 2 3, Phase 1/2 3, Phase 1 1) 2013: 12 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2014: 17 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2/3 2, Phase 2 3, Phase 1 4) 2015: 22 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 2/3 1, Phase 2 10, Phase 1 4) 2016: 24 trials (Observational 4, Not applicable 5, Phase 2 10, Phase 1/2 3, Phase 1 2) 2017: 22 trials (Observational 3, Not applicable 3, Phase 4 1, Phase 3 5, Phase 2 8, Phase 1 2) 2018: 19 trials (Observational 4, Phase 4 1, Phase 3 7, Phase 2 4, Phase 1/2 1, Phase 1 2) 2019: 15 trials (Observational 1, Not applicable 6, Phase 3 3, Phase 2 2, Phase 1 3) 2020: 27 trials (Observational 4, Not applicable 6, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 2 5, Phase 1 1) 2021: 14 trials (Observational 2, Not applicable 4, Phase 4 1, Phase 3 6, Phase 1 1) 2022: 31 trials (Observational 4, Not applicable 12, Phase 3 6, Phase 2/3 1, Phase 2 1, Phase 1/2 2, Phase 1 5) 2023: 15 trials (Observational 4, Not applicable 1, Phase 3 1, Phase 2 5, Phase 1/2 1, Phase 1 3) 2024: 16 trials (Observational 4, Not applicable 4, Phase 3 2, Phase 2/3 2, Phase 2 2, Phase 1 2) 2025: 14 trials (Observational 2, Not applicable 4, Phase 4 1, Phase 3 3, Phase 2 4)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 13
2025 14
2024 16
2023 15
2022 31
2021 14
2020 27
2019 15
2018 19
2017 22

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 14 trials starting in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 32 months from start to primary completion across 25 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 314 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Skin Diseases, Viral trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 51
Phase 1/2 19
Phase 2 88
Phase 2/3 12
Phase 3 100
Phase 4 29
Not applicable 82
Observational 74

How many Skin Diseases, Viral trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 10
Recruiting 29
Enrolling by invitation 2
Active, not recruiting 10
Completed 318

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Skin Diseases, Viral trials? (11)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 30
Merck Sharp & Dohme LLC 20
GlaxoSmithKline 19
Shanghai Bovax Biotechnology Co., Ltd. 12
Graceway Pharmaceuticals, LLC 8

Showing 5 of 11 sponsors.

Start your 14-day trial Email me all 11 sponsors as a PDF

Which drugs are being tested for Skin Diseases, Viral? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Famciclovir 9
ASP2151 6
Resiquimod 6
Candida Antigen 5
Foscarnet 4

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Acyclovir 5% 27
Valacyclovir arrow 26
CRYOTHERAPY 11
V503 4
ME-609 4

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Skin Diseases, Viral trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Abortion induced 140 4
Abortion spontaneous 128 4
Appendicitis 87 10
Overdose 44 4
Depression 32 4

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Skin Diseases, Viral? (13)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. The British journal of dermatology 2020 Yes
COVID-19 and the Skin. Actas dermo-sifiliograficas 2020 Yes
Extragenital cutaneous warts - clinical presentation, diagnosis and treatment. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2019 Yes
Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leukemia & lymphoma 2018 Yes
Herpes murine model as a biological assay to test dialyzable leukocyte extracts activity. Journal of immunology research 2015 Yes

Showing 5 of 13 publications.

Start your 14-day trial Email me all 13 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages